Clinical Trials Logo

Pneumonitis clinical trials

View clinical trials related to Pneumonitis.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04370834 Terminated - Pneumonia Clinical Trials

Tocilizumab for Patients With Cancer and COVID-19 Disease

Start date: May 28, 2020
Phase: Phase 2
Study type: Interventional

This phase II expanded access trial will study how well tocilizumab works in reducing the serious symptoms including pneumonitis (severe acute respiratory distress) in patients with cancer and COVID-19. COVID-19 is caused by the SARS-CoV-2 virus. COVID-19 can be associated with an inflammatory response by the immune system which may also cause symptoms of COVID-19 to worsen. This inflammation may be called "cytokine storm," which can cause widespread problems in the body. Tocilizumab is a medicine designed to block the action of a protein called interleukin-6 (IL-6) that is involved with the immune system and is known to be a key factor for problems with excessive inflammation. Tocilizumab is effective in treating "cytokine storm" from a type of cancer immunotherapy and may be effective in reducing the inflammatory response and "cytokine storm" seen in severe COVID-19 disease. Treating the inflammation may help to reduce symptoms, improve the ability to breathe without a breathing machine (ventilator), and prevent patients from having more complications.

NCT ID: NCT04040244 Terminated - Pneumonitis Clinical Trials

Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis

Start date: December 9, 2019
Phase: N/A
Study type: Interventional

This is a prospective pilot study investigating exhaled breath condensate analyses to quantify the variability over time of various biomarkers associated with symptomatic pneumonitis.

NCT ID: NCT03962725 Terminated - Respiratory Failure Clinical Trials

Avoiding Neuromuscular Blockers to Reduce Complications

Start date: August 7, 2019
Phase: Phase 4
Study type: Interventional

The goal of this study to evaluate whether eliminating the use of non-depolarizing neuromuscular blocking agents (NMBA) for maintenance of general anesthesia reduces postoperative pulmonary complications in higher risk patients.